Georgina Long

Georgina Long has spearheaded neoadjuvant immunotherapy approaches for resectable high-risk stage III melanoma, demonstrating that presurgical combination checkpoint blockade achieves pathological complete responses in the majority of patients and may offer superior long-term outcomes compared to adjuvant-only strategies. Her NEONAX and NADINA trials have shaped understanding of neoadjuvant combination nivolumab plus ipilimumab in resectable stage III disease. She has investigated MRD monitoring through ctDNA surveillance as a tool to guide adjuvant therapy intensification or de-escalation after neoadjuvant treatment. Her leadership of Australia's melanoma clinical trial network has advanced international melanoma treatment standards.